Quick Answer
Nuvation Bio Inc. reported Research And Development Expense of $115.11 million for the year ending 2025.
- Nuvation Bio Inc. showed an increase of +16.1% in Research And Development Expense from 2024 to 2025.
- This data is from Nuvation Bio Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $7.30 million | Q2 2020: $7.35 million | Q3 2020: $8.63 million | Q1 2021: $15.88 million | Q2 2021: $14.03 million | Q3 2021: $17.12 million | Q1 2022: $20.73 million | Q2 2022: $28.92 million | Q3 2022: $21.29 million | Q1 2023: $18.79 million | Q2 2023: $18.59 million | Q3 2023: $18.56 million | Q1 2024: $12.84 million | Q2 2024: $29.25 million | Q3 2024: $27.73 million | Q1 2025: $24.60 million | Q2 2025: $27.36 million | Q3 2025: $28.85 million.
- Over the full 6 years of available data (2020 to 2025), Nuvation Bio Inc.'s Research And Development Expense has grown by 253.1%.
- Historical annual values: Fiscal year 2025: $115.11 million | Fiscal year 2024: $99.12 million | Fiscal year 2023: $71.29 million | Fiscal year 2022: $87.82 million | Fiscal year 2021: $69.04 million | Fiscal year 2020: $32.60 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: